FR2823764B1 - Nouveaux polynucleotides et polypeptides du gene ifn alpha-17 - Google Patents

Nouveaux polynucleotides et polypeptides du gene ifn alpha-17

Info

Publication number
FR2823764B1
FR2823764B1 FR0105516A FR0105516A FR2823764B1 FR 2823764 B1 FR2823764 B1 FR 2823764B1 FR 0105516 A FR0105516 A FR 0105516A FR 0105516 A FR0105516 A FR 0105516A FR 2823764 B1 FR2823764 B1 FR 2823764B1
Authority
FR
France
Prior art keywords
gene
polypeptides
ifn alpha
novel polynucleotides
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0105516A
Other languages
English (en)
French (fr)
Other versions
FR2823764A1 (fr
Inventor
Jean Louis Escary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GenOdyssee SA
Original Assignee
GenOdyssee SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0105516A priority Critical patent/FR2823764B1/fr
Application filed by GenOdyssee SA filed Critical GenOdyssee SA
Priority to PT02742996T priority patent/PT1390543E/pt
Priority to EP02742996A priority patent/EP1390543B1/en
Priority to JP2002583669A priority patent/JP2004533240A/ja
Priority to DE60213402T priority patent/DE60213402T2/de
Priority to IL15841502A priority patent/IL158415A0/xx
Priority to RU2003133982/13A priority patent/RU2328528C2/ru
Priority to NZ529051A priority patent/NZ529051A/en
Priority to ES02742996T priority patent/ES2268054T3/es
Priority to AU2002338442A priority patent/AU2002338442B2/en
Priority to CNA028102193A priority patent/CN1509337A/zh
Priority to BR0209097-0A priority patent/BR0209097A/pt
Priority to AT02742996T priority patent/ATE334231T1/de
Priority to CA002444235A priority patent/CA2444235A1/en
Priority to KR10-2003-7013862A priority patent/KR20030093328A/ko
Priority to MXPA03009731A priority patent/MXPA03009731A/es
Priority to PCT/EP2002/005229 priority patent/WO2002086156A2/en
Priority to DK02742996T priority patent/DK1390543T3/da
Publication of FR2823764A1 publication Critical patent/FR2823764A1/fr
Priority to IL158415A priority patent/IL158415A/en
Priority to ZA200308114A priority patent/ZA200308114B/en
Priority to NO20034692A priority patent/NO20034692L/no
Priority to US10/691,653 priority patent/US7371819B2/en
Publication of FR2823764B1 publication Critical patent/FR2823764B1/fr
Application granted granted Critical
Priority to CY20061101453T priority patent/CY1107335T1/el
Priority to US12/098,557 priority patent/US20090004156A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
FR0105516A 2001-04-24 2001-04-24 Nouveaux polynucleotides et polypeptides du gene ifn alpha-17 Expired - Fee Related FR2823764B1 (fr)

Priority Applications (24)

Application Number Priority Date Filing Date Title
FR0105516A FR2823764B1 (fr) 2001-04-24 2001-04-24 Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
CNA028102193A CN1509337A (zh) 2001-04-24 2002-04-23 IFNα-17基因的新的多核苷酸和多肽
JP2002583669A JP2004533240A (ja) 2001-04-24 2002-04-23 ＩＦＮα−１７遺伝子の新規のポリヌクレオチドおよびポリペプチド
DE60213402T DE60213402T2 (de) 2001-04-24 2002-04-23 Neue polynukleotide und polypeptide des ifn alpha-17-gens
IL15841502A IL158415A0 (en) 2001-04-24 2002-04-23 NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNalpha-17 GENE
RU2003133982/13A RU2328528C2 (ru) 2001-04-24 2002-04-23 Полипептид, обладающий противовирусной, антипролиферативной и/или иммуномодулирующей активностью, выделенный полинуклеотид, кодирующий полипептид и их применение
NZ529051A NZ529051A (en) 2001-04-24 2002-04-23 New polynucleotides and polypeptides of the IFNalpha-17 gene
ES02742996T ES2268054T3 (es) 2001-04-24 2002-04-23 Nuevos polinucleotidos y polipeptidos del gen ifnalfa-17.
AU2002338442A AU2002338442B2 (en) 2001-04-24 2002-04-23 New polynucleotides and polypeptides of the IFN alpha-17 gene
EP02742996A EP1390543B1 (en) 2001-04-24 2002-04-23 New polynucleotides and polypeptides of the ifnalpha-17 gene
BR0209097-0A BR0209097A (pt) 2001-04-24 2002-04-23 Polinucleotìdeo isolado, métodos para identificar ou amplificar e para a genotipagem de todo ou parte de um polinucleotìdeo, para separar um polipeptìdeo, para obter um anticorpo imunoespecìfico, para identificar um agente e um composto entre um ou mais compostos a serem testados, para analisar as caracterìsticas biológicas de um paciente, para impedir ou tratar em um indivìduo uma doença e um distúrbio ou uma doença ligada à presença do polinucleotìdeo no genoma, para aumentar ou diminuir a atividade em um paciente do polipeptìdeo, para determinar estatisticamente associações relevantes entre pelo menos um snp e uma doença ou resistência à doença e para diagnosticar ou determinar um prognóstico de uma doença ou uma resistência a uma doença, vetor recombinante, célula hospedeira, polipeptìdeo, anticorpo imunoespecìfico, agente terapêutico, e, composto
AT02742996T ATE334231T1 (de) 2001-04-24 2002-04-23 Neue polynukleotide und polypeptide des ifn alpha-17-gens
PT02742996T PT1390543E (pt) 2001-04-24 2002-04-23 Novos polinucleótidos e polipéptidos do gene ifna-17
CA002444235A CA2444235A1 (en) 2001-04-24 2002-04-23 New polynucleotides and polypeptides of the ifn.alpha.-17 gene
KR10-2003-7013862A KR20030093328A (ko) 2001-04-24 2002-04-23 ＩＦＮα-17 유전자의 신규한 폴리뉴클레오티드 및폴리펩티드
PCT/EP2002/005229 WO2002086156A2 (en) 2001-04-24 2002-04-23 New polynucleotides and polypeptides of the ifn$g(a)-17 gene
DK02742996T DK1390543T3 (da) 2001-04-24 2002-04-23 Nye polynukleotider og polypeptider af IFNalfa-17-genet
MXPA03009731A MXPA03009731A (es) 2001-04-24 2002-04-23 Polinucleotidos y polipeptidos novedosos del gen de ifnalfa-17.
IL158415A IL158415A (en) 2001-04-24 2003-10-14 Polynucleotides and polypeptides of the 17th-INF gene
ZA200308114A ZA200308114B (en) 2001-04-24 2003-10-17 New polynucleotides and polypeptides of the IFNalpha-17 gene.
NO20034692A NO20034692L (no) 2001-04-24 2003-10-20 Nye polynukleotider og polypeptider av INF gamma-17 genet
US10/691,653 US7371819B2 (en) 2001-04-24 2003-10-24 Polypeptides of the IFNα-17 gene
CY20061101453T CY1107335T1 (el) 2001-04-24 2006-10-12 ΝΕΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΚΑΙ ΠΟΛΥΠΕΠΤΙΔΙΑ ΤΟΥ ΓΟΝΙΔΙΟΥ IFNα-17
US12/098,557 US20090004156A1 (en) 2001-04-24 2008-04-07 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNalpha17 GENE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0105516A FR2823764B1 (fr) 2001-04-24 2001-04-24 Nouveaux polynucleotides et polypeptides du gene ifn alpha-17

Publications (2)

Publication Number Publication Date
FR2823764A1 FR2823764A1 (fr) 2002-10-25
FR2823764B1 true FR2823764B1 (fr) 2003-12-12

Family

ID=8862643

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0105516A Expired - Fee Related FR2823764B1 (fr) 2001-04-24 2001-04-24 Nouveaux polynucleotides et polypeptides du gene ifn alpha-17

Country Status (22)

Country Link
US (2) US7371819B2 (no)
EP (1) EP1390543B1 (no)
JP (1) JP2004533240A (no)
KR (1) KR20030093328A (no)
CN (1) CN1509337A (no)
AT (1) ATE334231T1 (no)
AU (1) AU2002338442B2 (no)
BR (1) BR0209097A (no)
CA (1) CA2444235A1 (no)
CY (1) CY1107335T1 (no)
DE (1) DE60213402T2 (no)
DK (1) DK1390543T3 (no)
ES (1) ES2268054T3 (no)
FR (1) FR2823764B1 (no)
IL (2) IL158415A0 (no)
MX (1) MXPA03009731A (no)
NO (1) NO20034692L (no)
NZ (1) NZ529051A (no)
PT (1) PT1390543E (no)
RU (1) RU2328528C2 (no)
WO (1) WO2002086156A2 (no)
ZA (1) ZA200308114B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
FR2822845B1 (fr) * 2001-03-30 2003-12-12 Genodyssee Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
EP1418428A1 (en) * 2002-11-07 2004-05-12 GenOdyssee Method to provide natural therapeutic agents with high therapeutic index
CN102101886A (zh) * 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
KR102096224B1 (ko) 2011-10-28 2020-04-03 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
MX370377B (es) 2013-04-29 2019-12-11 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-cd38 y fusiones con interferón alfa-2b atenuado.
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
JP6730271B2 (ja) 2014-10-29 2020-07-29 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド インターフェロンα２Ｂバリアント
RU2620073C2 (ru) * 2015-06-02 2017-05-22 Федеральное государственное бюджетное учреждение "Государственный научный центр Институт иммунологии" Федерального медико-биологического агентства России Оптимизированный ген, кодирующий рекомбинантный белок - аналог интерферона альфа-17 человека
CN107653323B (zh) * 2016-07-23 2021-05-04 华中农业大学 团头鲂转铁蛋白基因snp分子标记及其应用
US20210380679A1 (en) 2018-10-11 2021-12-09 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
US20230124851A1 (en) 2018-10-11 2023-04-20 Inhibrx, lnc. B7h3 single domain antibodies and therapeutic compositions thereof
CA3114693A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. 5t4 single domain antibodies and therapeutic compositions thereof
AU2019356573A1 (en) 2018-10-11 2021-05-27 Inhibrx Biosciences, Inc. PD-1 single domain antibodies and therapeutic compositions thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801685A (en) * 1981-08-14 1989-01-31 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
JPS6156199A (ja) * 1984-08-27 1986-03-20 Shionogi & Co Ltd 新規ヒトインタ−フエロンα類
JP3732516B2 (ja) * 1995-02-09 2006-01-05 ノバルティス・アクチエンゲゼルシャフト タンパク質の製造法
AU761577C (en) * 1997-12-08 2004-02-05 Genentech Inc. Human interferon-epsilon: a type I interferon
EP1140144A4 (en) * 1998-12-31 2002-10-30 Viragen Inc METHODS AND COMPOSITION OF EXTREMELY PURIFIED NATURAL MIXTURES OF TYPE I INTERFERONS DERIVED FROM LEUCOCYTES
CN1451045A (zh) * 1999-10-07 2003-10-22 马克西根公司 IFN－α同系物

Also Published As

Publication number Publication date
FR2823764A1 (fr) 2002-10-25
US7371819B2 (en) 2008-05-13
RU2328528C2 (ru) 2008-07-10
NZ529051A (en) 2005-09-30
NO20034692L (no) 2003-12-19
IL158415A0 (en) 2004-05-12
BR0209097A (pt) 2005-04-19
ZA200308114B (en) 2005-01-17
KR20030093328A (ko) 2003-12-06
DE60213402D1 (de) 2006-09-07
JP2004533240A (ja) 2004-11-04
WO2002086156A3 (en) 2003-11-27
EP1390543B1 (en) 2006-07-26
EP1390543A2 (en) 2004-02-25
ES2268054T3 (es) 2007-03-16
CA2444235A1 (en) 2002-10-31
MXPA03009731A (es) 2005-03-07
NO20034692D0 (no) 2003-10-20
DK1390543T3 (da) 2006-11-27
CN1509337A (zh) 2004-06-30
AU2002338442B8 (en) 2002-11-05
PT1390543E (pt) 2006-12-29
WO2002086156A2 (en) 2002-10-31
US20090004156A1 (en) 2009-01-01
CY1107335T1 (el) 2012-12-19
ATE334231T1 (de) 2006-08-15
AU2002338442B2 (en) 2007-06-28
IL158415A (en) 2009-06-15
RU2003133982A (ru) 2005-01-20
US20040110715A1 (en) 2004-06-10
DE60213402T2 (de) 2007-08-23

Similar Documents

Publication Publication Date Title
DE60232870D1 (de) Neue polynukleotide und polypeptide des erythropoietingens
FR2823764B1 (fr) Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
CY1105650T1 (el) ΝΕΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΚΑΙ ΠΟΛΥΠΕΠΤΙΔΙΑ ΤΟΥ ΓΟΝΙΔΙΟΥ IFNα-21
BRPI0519766A2 (pt) proteases Ácidas féngicas
HUP0402271A2 (hu) Pseudoplectania nigrellá-ból származó antimikrobiális polipeptidek
ATE471370T1 (de) Varianten von beta-glukosidasen
ATE503009T1 (de) Polypeptide mit lipase-aktivität und diese kodierende polynukleotide
BR0215383A (pt) proteases que produzem resposta imunogênica alterada e métodos de fabricação e uso das mesmas
DE69942861D1 (de) Ldcam genannte moleküle
DE60235297D1 (de) Auf lps-reagierendes chs1/beige-ähnliches anker-gen und therapeutische anwendungen davon
SE9801455D0 (sv) New receptor
WO2002095067A3 (en) INTERFERON α-14 POLYMORPHISM
WO2003000896A3 (en) POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE
WO2002101048A3 (en) NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-7 GENE
ATE463572T1 (de) Rekombinanter faktor viii mit erhöhter spezifischer aktivität
WO2002083733A3 (en) Polynucleotides and polypeptides of the ifnalpha-6 gene
DK1664102T3 (da) Isoleret photoprotein mtclytin, samt dets anvendelse
DE60232812D1 (de) Allele des glucokinasegens von coryneformen bakterien
EP1236800A3 (en) Nucleic acids encoding interferon alpha 2, containing single nucleotide polymorphisms and methods of use thereof
WO2002072632A3 (en) Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof.
WO2002101002A3 (en) Identification of snps the hgv-v gene
DE60231970D1 (de) Neurovirulenter stamm des west-nile-virus und anwendungen davon
DE60229966D1 (de) Diabetesmodell
HUP0203164A2 (hu) Koleszterin-metabolizmussal kapcsolatos betegségekben érintett gének expressziós termékei
ATE374260T1 (de) Asthma-assoziiertes gen

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20101230